Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Similar documents
coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

CHEMOTHERAPY

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human


Fig.1 Chemical structure of BAY o 9867


epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.

Fig. 1 Chemical structure of DL-8280


VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus


Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

Fig. 1 Chemical structure of KW-1070


Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent



CHEMOTHERAPY MAY. 1988

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

Table1MIC of BAY o 9867 against standard strains

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

1272 CHEMOTHERAPY MAR. 1975

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -

VOL.42 S-1

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin



Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str

Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

THE JAPANESE JOURNAL OF ANTIBIOTICS ( 37 ) methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof

日本化学療法学会雑誌第61巻第6号




VOL. 34 S-2 CHEMOTH8RAPY 913


Fig. 1 Chemical structure of norfioxacin (AM-715)

CHEMOTHERAPY




VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum

VOL.27 S-5 CHEMOTHERAPY Table 1 Clinical evaluations of cefamandole on UTI (1) Benign prostatic hypertrophy (2) Transurethral resection of bladder tum

208 ( 2 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 Cefditoren pivoxil (CDTR-PI) MS MS 10%


CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc

Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)


VOL. 43 NO. 4

CHEMOTHERAPY JUNE 1986

CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC


CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

日本化学療法学会雑誌第59巻第5号

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

CHEMOTHERAPY FEB Table 1 Background of volunteers

日本化学療法学会雑誌第64巻第4号

Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227,

CHEMOTHERAPY




988 CHEMOTHERAPY NOV. 1971

日本化学療法学会雑誌第55巻第S-1号

日本化学療法学会雑誌第56巻第1号

Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s

日本化学療法学会雑誌第53巻第S-3号

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia

CHEMOTHERAPY

日本化学療法学会雑誌第58巻第4号

Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det



Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination


Key words: Antibodies to Leptospira, Tokyo, Uveitis

Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis

VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin

Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo

VOL.27S-1 CHEMOTHERAPY 109 Klebsiella, Proteus, Pseudomonas Streptococcus Fig. 1 Concentration in blood and in CSF after intravenous drip infusion of

CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

Transcription:

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient, In: inpatient p.tbc.: pulmonary tuberculosis NE: not examinable NF: normal flora

Table 2-2. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient, In: inpatient p.tbc.: pulmonary tuberculosis DPB: diffuse panbronchiolitis PF: pulmonary fibrosis NE: not examinable NF: normal flora

Table 3. Clinical effect classified by diagnosis Table 4. Bacteriological effect on causative organisms

VOL. 43 S-1 Table 5. Laboratory findings in patients before and after administration of grepafloxacin B: before A: after

2) Imada T, Miyazaki S, Nishida M, Yamaguchi K and Goto S: In vitro and In vivo antibacterial activities of new quinolone, OPC-17116. Antimicrob Agents Chemother 36: 573-579, 1992 3) Tira K, Koga H and Kohno S: Accumulation of a new developed fluoroquinolone, OPC-17116, by human polymorphonuclear leukocytes. Antimicrob Agents Chemother 37: 1877-1881, 1993

VOL. 43 S-1 Antimicrobial effect of grepafloxacin and its clinical study in patients with chronic airway infection Shigeki Odagiri, Kaneo Suzuki, Hiroshi Takahashi and Kenichi Takahashi Department of Respiratory Diseases, Kanagawa Prefectural Cardiovascular and Respiratory Disease Center 6-16-1 Tomiokahigashi, Kanazawa-ku, Yokohama 236, Japan The antimicrobial effect of grepafloxacin (GPFX), a newly developed quinolone derivative for oral use, on clinicaly isolated strains was examined in comparison with those of ofloxacin (OFLX), ciprofloxacin (CPFX), sparfloxacin (SPFX), and fleroxacin (FLRX). The antimicrobial effects of GPFX on MSSA, MRSA and Streptococcus pneumoniae among gram-positive bacilli were, like SPFX, superior to those of other tested drugs. In the case of gram-negative bacilli, the antimicrobial effect of GPFX was sufficient on Klebsiella pneumoniae although slightly inferior to CPFX, almost equal to those of other drugs on Haemophilus influenzae, and superior to those of other drugs on Moraxella (Branhamella) catarrhalis, similar to the findings for SPFX. Against Pseudomonas aeruginosa, the antimicrobial effect was superior to that of the others but was slightly inferior to CPFX. GPFX was orally administered to 20 patients with respiratory infection, mainly consisting of chronic airway infection, to examine its clinical efficacy and safety. The clinical result was effective in 17 cases and slightly effective in 3 cases, an efficacy rate of 85.0%. Bacteriologically, 13 pathogenic strains (P. aeruginosa, S. pneumoniae, H. influenzae, K. pneumoniae, Aeromonas hydrophila, Proteus vulgaris, K. pneumoniae and Xanthomonas maltophilia) were specified from 12 cases. Based on the bacteriological effect of GPFX on these 13 strains, the elimination rate was calculated as 53.8%. Side effects were observed in 3 cases (incidence: 15.0%): vertigo, drowsiness/numbness and wheal in 1 case each. Abnormal laboratory values were observed in 2 cases (incidence: 10.0%): increased serum GOT/GPT/Al-P and increased urinary urobilinogen in 1 case each.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック